Johnson Investment Counsel Inc. Acquires 211 Shares of LeMaitre Vascular, Inc. $LMAT

Johnson Investment Counsel Inc. raised its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 0.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,639 shares of the medical instruments supplier’s stock after purchasing an additional 211 shares during the quarter. Johnson Investment Counsel Inc. owned 0.13% of LeMaitre Vascular worth $2,462,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Opal Wealth Advisors LLC bought a new stake in shares of LeMaitre Vascular during the first quarter worth $26,000. Geneos Wealth Management Inc. lifted its position in shares of LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 398 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of LeMaitre Vascular during the first quarter worth $50,000. US Bancorp DE raised its holdings in shares of LeMaitre Vascular by 36.0% in the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier’s stock valued at $117,000 after acquiring an additional 368 shares in the last quarter. Finally, Strs Ohio bought a new stake in shares of LeMaitre Vascular in the first quarter valued at about $168,000. 84.64% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director John A. Roush sold 6,561 shares of the business’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $92.55, for a total transaction of $607,220.55. Following the sale, the director owned 2,916 shares in the company, valued at approximately $269,875.80. The trade was a 69.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO George W. Lemaitre sold 100,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total value of $9,351,000.00. Following the sale, the chief executive officer owned 1,727,003 shares in the company, valued at $161,492,050.53. The trade was a 5.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 120,815 shares of company stock worth $11,280,206 over the last ninety days. Insiders own 9.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on LMAT shares. Cantor Fitzgerald lifted their price objective on LeMaitre Vascular from $92.00 to $95.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Barrington Research restated an “outperform” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a report on Tuesday, September 23rd. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, LeMaitre Vascular presently has an average rating of “Moderate Buy” and an average target price of $97.60.

LeMaitre Vascular Price Performance

LMAT opened at $85.31 on Tuesday. The business’s 50-day moving average is $92.21 and its two-hundred day moving average is $86.39. LeMaitre Vascular, Inc. has a 1 year low of $71.42 and a 1 year high of $109.58. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. The firm has a market capitalization of $1.93 billion, a PE ratio of 41.41, a price-to-earnings-growth ratio of 2.22 and a beta of 0.77.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The company had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. During the same quarter in the previous year, the firm earned $0.52 earnings per share. The firm’s quarterly revenue was up 15.0% compared to the same quarter last year. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st were paid a dividend of $0.20 per share. The ex-dividend date was Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. LeMaitre Vascular’s payout ratio is presently 38.83%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.